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Received 6 October 2012; revised 8 January 2013; accepted 13 January 2013Abstract Radiation therapy is an effective cancer treatment that is constantly being transformed by
technological innovation. Dedicated devices for fraction-by-fraction imaging and guidance within
the treatment room have enabled image guided radiation therapy (IGRT) allowing clinicians to
pursue highly conformal dose distributions, higher dose prescriptions, and shorter fractionation
schedules. Capitalizing on IGRT-enabled accuracy and precision requires a strong link between
IGRT practices and planning target volume (PTV) design. This is clearly central to high quality,
safe radiation therapy. Failure to properly apply IGRT methods or to coordinate their use with an
appropriate PTV margin can result in a treatment that is ‘precisely wrong’. The white paper
summarized in this executive summary recommends foundational elements and specific activities
to maximize the safety and effectiveness of IGRT.
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This executive summary provides a brief description of
the content of the report on safety considerations for image
guided radiation therapy (IGRT) and is intentionally
limited in length and content. Please see the full report
published online only at www.practicalradonc.org. This
abridged version is not intended to replace the full length
report but rather to highlight key elements of the report.
The full report provides additional background informa-
tion for those less familiar with IGRT.Table 1 Recommendations to establish a foundation for
safe and effective IGRT practices
Recommendation
1. Establish a multi-professional team responsible for
IGRT activities.
2. Establish and monitor a program of daily, monthly, and
annual QA for all new or existing IGRT sub-systems.
3. Provide device- and process-specific training for all staff
operating IGRT systems or responsible for IGRT delivery.White papers on patient safety in
radiation therapy
The full report is part of a series of white papers
addressing patient safety commissioned by the American
Society for Radiation Oncology (ASTRO) Board of
Directors as part of ASTRO's Target Safely Campaign.
The full length document was approved by the ASTRO
Board of Directors on June 23, 2012 and has been
endorsed by the American Association of Physicists in
Medicine, the American Association of Medical Dosime-
trists, and the American Society of Radiologic Technol-
ogists. The document has also been reviewed and accepted
by the American College of Radiology's Commission on
Radiation Oncology. These organizations have a long
history of supporting efforts toward improving patient
safety in the United States.
This report is related to other published reports of the
ASTRO white paper series on patient safety, including
those on intensity modulated radiation therapy (IMRT)
and stereotactic body radiation therapy (SBRT), and those
still in preparation. There are sections of this report that
defer to guidance in these reports.4. Perform ‘end-to-end’ testing for all new IGRT procedures
(from simulation to dose delivery) and document
performance prior to clinical release.
5. Establish process-specific documentation and procedures
for IGRT.
6. Clearly identify who is responsible for approval of IGRT
correction decision and the process whereby this decision
is made and documented.
7. Establish and document site-specific planning procedures;
specifically, the procedure for defining PTV margins. Link
these planning procedures to IGRT procedures.
8. Multi-professional peer-review of PTV volumes. Peer-
review of GTV/CTV volumes by ROs.
9. Verify proper creation and transfer of IGRT reference
data (PTV, OARs, DRRs, etc) to IGRT system.
10. Establish a reporting mechanism for IGRT-related
variances in the radiation treatment process.
GTV/CTV, gross tumor volume/clinical target volume; IGRT, image
guided radiation therapy; PTV, planning target volume; OARs, organs
at risk; QA, quality assurance; ROs, radiation oncologists.Image guided radiation therapy
Highly tailored, patient-specific dose distributions can
now be generated using 3-dimensional (3D) imaging and
inverse planning techniques to design IMRT. The
increased dose conformality heightens the need to assure
accurate and precise localization of the target and normal
structures prior to or during each treatment fraction, and
has driven the integration of imaging technologies (and/or
tracking systems) into the treatment room and onto the
treatment machine. For the purpose of this paper, the
activities associated with the use of these systems are
referred to as image guided radiation therapy (IGRT).
IGRT techniques can substantially reduce geometric
positioning errors that can occur between treatment
planning and delivery and enable clinicians to pursuetreatments that are more conformal. It also increases the
reliance of these treatments on the IGRT system
performance. Failure to assure this performance can result
in treatments that are “precisely wrong.”Nature of safety concerns
IGRT is a method of assuring the geometric-targeting
elements of the treatment for the individual patient as well
as a method of maintaining a level of geometric targeting
performance for a population of patients that allows
confident use of smaller planning target volume (PTV)
margins in the planning process. The use of smaller PTV
margins is a delicate issue that requires strong coordina-
tion between the planning process and the image guidance
activities at the treatment unit. Failure to reproduce the
expected geometric accuracy and precision for which
the plan was designed could result in an under-dose to
the target or an over-dose to surrounding tissues. This
feedback loop between the actions at the treatment
machine and the planning process heightens the safety-
related issues associated with IGRT. Specifically, the need
for increased communication between the professions is
heightened. A radiation therapist applying IGRT technol-
ogy and a dosimetrist/physicist working with the radiation
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confident that the expected precision and accuracy are
actually achieved. The various points of failure that raise
safety concerns in IGRT are illustrated in Fig 1 (available
online only at www.practicalradonc.org) and briefly
described in the caption. These are expanded upon in the
full report. The full report also identifies foundational
elements that should be in place to assure well-placed
confidence in IGRT technology. This list is presented in
an abridged form here in Table 1. Additional activities that
can be used by individual clinics to reassess and
strengthen the safety of their IGRT practices are presented
in the full length document. Some of the key consider-
ations affecting the safety of IGRT practice are briefly
outlined below.Commissioning and continuing quality
assurance of IGRT technologies
A substantial body of literature on commissioning and
quality assurance (QA) of IGRT systems is available for
the community. These address both the general principles
of IGRT as well as provide technology-specific guidance.
Clinical programs should follow the general guidelines of
TG-142 on medical accelerator QA, which includes a
section that provides guidelines specific for planar and
cone beam kV and MV imaging and lists daily, monthly
and annual QA tests and their respective tolerances.1
These should be supplemented by those recommended in
IGRT technology-specific task group reports of the
American Association of Physicists in Medicine.The link between the PTV margin and
IGRT practice
IGRT systems are capable of accurately targeting
unambiguous objects to submillimeter levels, especially
in phantom-type studies. However, this will not be
achieved in the clinical context. Image registration of
actual patient anatomy, variations between observers, and
imperfect corrections will result in delivery that is less
precise and less accurate than that shown in phantom
studies. It is the accuracy and precision that can be
obtained during clinical use that should be considered in
the design of the PTV margin. Clinics need to focus on the
link between the PTV margins used in treatment planning
and the performance and application of the technology in
the treatment room. This requires greater communication
between the radiation oncology professions in the clinic
and is supported by the creation of an “IGRT team,”
including medical physicists, medical dosimetrists, radia-
tion therapists, and radiation oncologists.Protocols for image acquisition and
interpretation
IGRT needs to be performed under the direction of
commissioned procedures to assure the clinical use of
the system continues to be consistent with that
characterized during commissioning. These protocols
should address every facet of the IGRT procedure,
including the imaging technique, imaging dose, defini-
tion of structures (normal and target), alignment
methods, action thresholds (translate/rotate), decision-
making process, and documentation.2 These protocols
are best designed by the IGRT team, where the needs of
the clinician, operational concerns of the therapist, and
technical guidance of the medical physicist can be
expressed and addressed.3Education, training, and human resources
IGRT technologies and practice bring a great deal of
additional information into the radiation therapy treatment
(RTT) process. In contrast to the pre-IGRT era, RTTs at
the treatment unit may find that they handle more
volumetric imaging data (eg, N20 cone-beam CT,
ultrasound, or megavoltage CT scans) each day than
does any other profession within the program. In addition,
these images each require analysis and a decision that
affects patient treatment. Operating the imaging systems,
interpreting of volumetric images, and making image-
guidance decisions push the limits of the existing training
curricula of all professions involved: radiation therapists,
medical dosimetrists, oncologists, and medical physicists.
In addition, it also raises new challenges in terms of inter-
professional dependencies and dialog.4 Appropriate staff-
ing levels are also a critical part of a program's safe
deployment of IGRT technology, requiring additional
medical physics staffing for the commissioning, imple-
mentation, on-going QA, and operational stages.5–7 Staff
requirements should be reviewed when it is decided IGRT
equipment is to be purchased and should examine the
additional time required for the quality control testing of
IGRT systems, as well as the time required for daily
decision-making processes during IGRT practice.Summary
IGRT is a powerful tool that enables radiation
oncologists to further increase the conformality of
radiation delivery. It is time and resource intensive and
heightens the need for process-oriented thinking and inter-
professional communication. The safe application of
IGRT technology is not limited to the operation of the
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treatment planning process where treatment plans are
developed under the assumption that IGRT performance
will be present at the time of treatment. The recommen-
dations in the full length report are intended to provide
guidance to aid clinics in implementing the foundational
elements for safe use of IGRT. These include both
programmatic components and patient-specific efforts. In
addition, a number of recommended activities are
presented to educate and engage various stakeholders
on the opportunities to assure the safe use of IGRT.
Finally, it is expected that there will be further advances
in IGRT technology and the establishment of a sound
foundation will assure these technologies are safely
deployed in the clinic.Acknowledgments
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